Ulcerative colitis: Current treatment strategies and future prospects

Therapeutic Advances in Gastroenterology

Volumn 2, Issue 2, 2009, Pages 99-108

  Garud, Sagar ^a   Peppercorn, Mark A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adalimumab; Certolizumab pegol; Sagramostin; Tumor necrosis factor alpha inhibitors; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; APRISO; AZATHIOPRINE; BALSALAZIDE; CALCIUM; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; FISH OIL; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; NICOTINE; OLSALAZINE; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; ROSIGLITAZONE; SAGRAMOSTIN; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ABDOMINAL DISCOMFORT; ALTERNATIVE MEDICINE; ANOREXIA; BACTERIAL PNEUMONIA; BEDTIME DOSAGE; BIRTH DEFECT; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLITIS; COLON; CONGENITAL DISORDER; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; FULMINANT COLITIS; GROWTH DISORDER; HEADACHE; HEPATITIS; HIRSUTISM; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; ILEITIS; INFUSION REACTION; INJECTION SITE REACTION; KIDNEY FAILURE; LIVER TOXICITY; LOW BIRTH WEIGHT; LOW DRUG DOSE; LYMPHOMA; MALAISE; MALE INFERTILITY; NAUSEA; NEPHRITIS; NEPHROTOXICITY; OOCYTE; OPPORTUNISTIC INFECTION; PANCOLITIS; PANCREATITIS; PERICARDITIS; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL; PROCTITIS; PROCTOSIGMOIDITIS; RASH; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; STILLBIRTH; SUBMUCOSA; TRICHURIS; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VERNER MORRISON SYNDROME; VISUAL DISORDER; VOMITING;

EID: 77953429865     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09102329     Document Type: Review

References (55)

1. Armenti, V.T., Ahlswede, K.M., Ahlswede, B.A., Jarrell, B.E., Moritz, M.J. and Burke, J.F. (1994) National Transplantation Pregnancy Registry - outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients, Transplantation 57: 502-506.
2. Arnott, I.D., McDonald, D., Williams, A. and Ghosh, S. (2001) Clinical use of infliximab in Crohn's disease: the Edinburgh experience, Aliment Pharmacol Ther 15: 1639-1646.
3. Aslan, A. and Triadafilopoulos, G. (1992) Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study, Am J Gastroenterol 87: 432-437.
4. Baron, J.H., Connell, A.M., Lennard-Jones, J.E. and Jones, F.A. (1962) Sulphasalazine and salicylazosulphadimidine in ulcerative colitis, Lancet 1: 1094-1096.
5. Borkow, G., Leng, Q., Weisman, Z., Stein, M., Galai, N., Kalinkovich, A. et al. (2000) Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy, J Clin Invest 106: 1053-1060.
6. Bossa, F., Fiorella, S., Caruso, N., Accadia, L., Napolitano, G., Valvano, M.R. et al. (2007) Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial, Am J Gastroenterol 102: 601-608.
7. Cockburn, I., Krupp, P. and Monka, C. (1989) Present experience of sandimmun in pregnancy, Transplant Proc 21: 3730-3732.
8. Cohen, R.D., Stein, R. and Hanauer, S.B. (1999) Intravenous cyclosporin in ulcerative colitis: a five-year experience, Am J Gastroenterol 94: 1587-1592.
9. Craven, P.A., Pfanstiel, J., Saito, R. and Derubertis, F.R. (1987) Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity, Gastroenterology 92: 1998-2008.
10. Cuffari, C., Hunt, S. and Bayless, T. (2001) Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease, Gut 48: 642-646.
11. Dick, A.P., Grayson, M.J., Carpenter, R.G. and Petrie, A. (1964) Controlled trial of sulphasalazine in the treatment of ulcerative colitis, Gut 5: 437-442.
12. Dissanayake, A.S. and Truelove, S.C. (1973) A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (salazopyrin), Gut 14: 923-926.
13. Fleig, W.E., Laudage, G., Sommer, H., Wellmann, W., Stange, E.F. and Riemann, J. (1988) Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis, Digestion 40: 173-180.
14. Geborek, P., Bladstrom, A., Turesson, C., Gulfe, A., Petersson, I.F., Saxne, T. et al. (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas, Ann Rheum Dis 64: 699-703.
15. Gonzalez-Lama, Y., Gisbert, J.P. and Mate, J. (2006) The role of tacrolimus in inflammatory bowel disease: a systematic review, Dig Dis Sci 51: 1833-1840.
16. Hawkey, C.J., Boughton-Smith, N.K. and Whittle, B.J. (1985) Modulation of human colonic arachidonic acid metabolism by sulfasalazine, Dig Dis Sci 30: 1161-1165.
17. Jarnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlen, P., Granno, C. et al. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study, Gastroenterology 128: 1805-1811.
18. Kornbluth, A., Present, D.H., Lichtiger, S. and Hanauer, S. (1997) Cyclosporin for severe ulcerative colitis: a user's guide, Am J Gastroenterol 92: 1424-1428.
19. Kozarek, R.A., Patterson, D.J., Gelfand, M.D., Botoman, V.A., Ball, T.J. and Wilske, K.R. (1989) Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease, Ann Intern Med 110: 353-356.
20. Lewis, J.D., Lichtenstein, G.R., Deren, J.J., Sands, B.E., Hanauer, S.B., Katz, J.A. et al. (2008) Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial, Gastroenterology 134: 688-695.
21. Lichtiger, S., Present, D.H., Kornbluth, A., Gelernt, I., Bauer, J., Galler, G. et al. (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N Engl J Med 330: 1841-1845.
22. Loftus Jr, E.V. (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, Gastroenterology 126: 1504-1517.
23. Mackey, A.C., Green, L., Liang, L.C., Dinndorf, P. and Avigan, M. (2007) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease, J Pediatr Gastroenterol Nutr 44: 265-267.
24. Madden, M.V., McIntyre, A.S. and Nicholls, R.J. (1994) Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis, Dig Dis Sci 39: 1193-1196.
25. Mate-Jimenez, J., Hermida, C., Cantero-Perona, J. and Moreno-Otero, R. (2000) 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease, Eur J Gastroenterol Hepatol 12: 1227-1233.
26. Mogadam, M., Dobbins 3rd., W.O., Korelitz, B.I. and Ahmed, S.W. (1981) Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome, Gastroenterology 80: 72-76.
27. Mulder, C.J., Tytgat, G.N., Weterman, I.T., Dekker, W., Blok, P., Schrijver, M. et al. (1988) Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis, Gastroenterology 95: 1449-1453.
28. Neal, T.M., Winterbourn, C.C. and Vissers, M.C. (1987) Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine, Biochem Pharmacol 36: 2765-2768.
29. Ogata, H., Matsui, T., Nakamura, M., Iida, M., Takazoe, M., Suzuki, Y. et al. (2006) A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis, Gut 55: 1255-1262.
30. Oren, R., Arber, N., Odes, S., Moshkowitz, M., Keter, D., Pomeranz, I. et al. (1996) Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial, Gastroenterology 110: 1416-1421.
31. Plevy, S., Salzberg, B., van Assche, G., Regueiro, M., Hommes, D., Sandborn, W. et al. (2007) A Phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis, Gastroenterology 133: 1414-1422.
32. Pullan, R.D., Rhodes, J., Ganesh, S., Mani, V., Morris, J.S., Williams, G.T. et al. (1994) Transdermal nicotine for active ulcerative colitis, N Engl J Med 330: 811-815.
33. Rao, S.S., Dundas, S.A., Holdsworth, C.D., Cann, P.A., Palmer, K.R. and Corbett, C.L. (1989) Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study, Gut 30: 675-679.
34. Rayner, C.K., McCormack, G., Emmanuel, A.V. and Kamm, M.A. (2003) Long-term results of low-dose intravenous cyclosporin for acute severe ulcerative colitis, Aliment Pharmacol Ther 18: 303-308.
35. Rembacken, B.J., Snelling, A.M., Hawkey, P.M., Chalmers, D.M. and Axon, A.T. (1999) Non-pathogenic escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial, Lancet 354: 635-639.
36. Riley, S.A., Mani, V., Goodman, M.J., Herd, M.E., Dutt, S. and Turnberg, L.A. (1988) Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse, Gut 29: 669-674.
37. Rutgeerts, P., Sandborn, W.J., Feagan, B.G., Reinisch, W., Olson, A., Johanns, J. et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med 353: 2462-2476.
38. Sandborn, W.J. (1994) Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment, Gastroenterology 107: 1856-1860.
39. Sandborn, W.J., Tremaine, W.J., Offord, K.P., Lawson, G.M., Petersen, B.T., Batts, K.P. et al. (1997) Transdermal nicotine for mildly to moderately active ulcerative colitis. a randomized, double-blind, placebo-controlled trial, Ann Intern Med 126: 364-371.
40. Seidner, D.L., Lashner, B.A., Brzezinski, A., Banks, P.L., Goldblum, J., Fiocchi, C. et al. (2005) An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial, Clin Gastroenterol Hepatol 3: 358-369.
41. Shale, M., Kanfer, E., Panaccione, R. and Ghosh, S. (2008) Hepatosplenic T cell lymphoma in inflammatory bowel disease, Gut 57: 1639-1641.
42. Shanahan, F., Niederlehner, A., Carramanzana, N. and Anton, P. (1990) Sulfasalazine inhibits the binding of TNF alpha to its receptor, Immunopharmacology 20: 217-224.
43. Stenson, W.F., Cort, D., Rodgers, J., Burakoff, R., Deschryver-Kecskemeti, K., Gramlich, T.L. et al. (1992) Dietary supplementation with fish oil in ulcerative colitis, Ann Intern Med 116: 609-614.
44. Sternthal, M.B., Murphy, S.J., George, J., Kornbluth, A., Lichtiger, S. and Present, D.H. (2008) Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease, Am J Gastroenterol 103: 937-943.
45. Summers, R.W., Elliott, D.E., Urban Jr J.F., Thompson, R.A. and Weinstock, J.V. (2005) Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial, Gastroenterology 128: 825-832.
46. Tanis, A.A. (1998) Azathioprine in inflammatory bowel disease, a safe alternative? Mediators Inflamm 7: 141-144.
47. Thomas, G.A., Rhodes, J., Mani, V., Williams, G.T., Newcombe, R.G., Russell, M.A. et al. (1995) Transdermal nicotine as maintenance therapy for ulcerative colitis, N Engl J Med 332: 988-992.
48. Timmer, A., McDonald, J.W. and MacDonald, J.K., (2007) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev: CD000478.
49. Tursi, A., Brandimarte, G., Giorgetti, G.M., Forti, G., Modeo, M.E. and Gigliobianco, A. (2004) Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis, Med Sci Monit 10: P1126-P1131
50. Turunen, U.M., Farkkila, M.A., Hakala, K., Seppala, K., Sivonen, A., Ogren, M. et al. (1998) Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study, Gastroenterology 115: 1072-1078.
51. van Assche, G., D'haens, G., Noman, M., Vermeire, S., Hiele, M., Asnong, K. et al. (2003) Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis, Gastroenterology 125: 1025-1031.
52. van Hogezand, R.A. and Hamdy, N.A. (2006) Skeletal morbidity in inflammatory bowel disease, Scand J Gastroenterol Suppl. 243: 59-64.
53. Wiederrecht, G., Lam, E., Hung, S., Martin, M. and Sigal, N. (1993) The mechanism of action of FK-506 and cyclosporin A, Ann N Y Acad Sci 696: 9-19.
54. World, M.J., Stevens, P.E., Ashton, M.A. and Rainford, D.J. (1996) Mesalazine-associated interstitial nephritis, Nephrol Dial Transplant 11: 614-621.
55. Zocco, M.A., Dal Verme, L.Z., Cremonini, F., Piscaglia, A.C., Nista, E.C., Candelli, M. et al. (2006) Efficacy of lactobacillus GG in maintaining remission of ulcerative colitis, Aliment Pharmacol Ther 23: 1567-1574.